利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

140 条记录 (耗时 0.046 秒)

    Human sarcoma-associated antigens
    54.
    发明授权
    Human sarcoma-associated antigens 失效
    人肉瘤相关抗原

    公开(公告)号：US07560537B2

    公开(公告)日：2009-07-14

    申请号：US10260708

    申请日：2002-09-30

    申请人： Matthew J. Scanlan ,  Sang-Yull Lee ,  Lloyd J. Old

    发明人： Matthew J. Scanlan ,  Sang-Yull Lee ,  Lloyd J. Old

    IPC分类号： C07H21/02

    CPC分类号： C07K14/4748 ,  C07H21/04 ,  C07K16/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  G01N33/57488

    摘要： The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35.

    摘要翻译： 本发明涉及肉瘤相关抗原和编码它们的核酸分子。 本发明进一步涉及与肉瘤相关的核酸分子，多肽及其片段在用于诊断和治疗诸如癌症的疾病的方法和组合物中的用途。 更具体地，本发明涉及新型癌/睾丸（CT）抗原NY-SAR-35的发现。

    Method for determining oncogenic activity of a substance
    55.
    发明授权
    Method for determining oncogenic activity of a substance 失效
    确定物质致癌活性的方法

    公开(公告)号：US06428969B1

    公开(公告)日：2002-08-06

    申请号：US09473456

    申请日：1999-12-28

    申请人： Robert Schreiber ,  Lloyd J. Old

    发明人： Robert Schreiber ,  Lloyd J. Old

    IPC分类号： G01N33574

    CPC分类号： A61K49/0008

    摘要： A method for screening substances for oncogenic activity is disclosed. The method involves administering the substance to an animal lacking responsiveness to interferon&ggr; and detecting a higher frequency or earlier time of tumor formation in the test animal compared to control animals. In addition, a method is provided for predicting the aggressiveness of a tumor in a patient.

    摘要翻译： 公开了用于筛选致癌活性物质的方法。 该方法包括将物质施用于对照干扰素的反应性不良的动物中，并且与对照动物相比，检测测试动物中较高频率或更早的肿瘤形成时间。 此外，提供了一种用于预测患者肿瘤侵袭性的方法。

    Method for treating cancers
    56.
    发明授权
    Method for treating cancers 有权
    治疗癌症的方法

    公开(公告)号：US06348195B1

    公开(公告)日：2002-02-19

    申请号：US09602709

    申请日：2000-06-26

    申请人： Thomas Paul Wallace ,  William Joseph Harris ,  Francis Joseph Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    发明人： Thomas Paul Wallace ,  William Joseph Harris ,  Francis Joseph Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    IPC分类号： A61K39395

    CPC分类号： G01N33/6854 ,  G01N33/57484 ,  G01N33/6833

    摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumor cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.

    摘要翻译： 本发明提供了针对抗原LK26特异的几种人源化鼠抗体的产生，其被鼠抗体LK26识别。 该抗原在所有绒毛膜癌，畸胎癌和肾癌细胞系中表达，而不在白血病，淋巴瘤，神经外胚层衍生的和上皮性肿瘤细胞系的细胞系（除了上皮细胞系的一小部分之外）上表达。 此外，肾癌细胞株表达LK26抗原时，肾上皮细胞不正常。 类似地，除了滋养层之外，所有正常的成年和胎儿组织都检测到LK26表型阴性。 本发明还提供编码人源化LK26特异性抗体的许多多核苷酸，用于产生人源化LK26特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。 本发明还提供了使用人源化LK26特异性抗体检测癌细胞（体外和体内）的方法。 另外，本发明提供使用LK26特异性抗体治疗癌症的方法。

    Methods for detecting cancer cells by using humanized antibodies which bind specifically to FB5 antigen
    57.
    发明授权
    Methods for detecting cancer cells by using humanized antibodies which bind specifically to FB5 antigen 有权
    通过使用特异性结合FB5抗原的人源化抗体检测癌细胞的方法

    公开(公告)号：US06217868B1

    公开(公告)日：2001-04-17

    申请号：US09184198

    申请日：1998-11-02

    申请人： Thomas Paul Wallace ,  Francis Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    发明人： Thomas Paul Wallace ,  Francis Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    IPC分类号： A61K39395

    CPC分类号： C07K16/30 ,  C07K2317/24 ,  C07K2319/00

    摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.

    摘要翻译： 本发明提供了针对抗原FB5特异的几种人源化鼠抗体的产生，其被鼠抗体FB5识别。 FB5抗原在广泛恶性肿瘤的血管内皮细胞的腔表面上表达。 本发明还提供编码人源化FB5特异性抗体的许多多核苷酸，用于产生人源化FB5特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。 本发明还提供使用人源化FB5特异性抗体检测癌细胞（体外和体内）的方法。 另外，本发明提供了使用FB5特异性抗体治疗癌症的方法。

    Compositions and method for treatment of cancer using monoclonal antibody against G.sub.D3 ganglioside together with IL-2
    59.
    发明授权
    Compositions and method for treatment of cancer using monoclonal antibody against G.sub.D3 ganglioside together with IL-2 失效
    使用针对GD3神经节苷脂的单克隆抗体与IL-2一起治疗癌症的组合物和方法

    公开(公告)号：US5104652A

    公开(公告)日：1992-04-14

    申请号：US549238

    申请日：1990-07-05

    申请人： Alan N. Houghton ,  Karl Welte ,  Glenn Miller ,  Paul Chapman ,  Lloyd J. Old

    发明人： Alan N. Houghton ,  Karl Welte ,  Glenn Miller ,  Paul Chapman ,  Lloyd J. Old

    IPC分类号： A61K39/395 ,  C12N5/02

    CPC分类号： A61K39/395 ,  Y10S424/809 ,  Y10S530/864

    摘要： Cell surface gangliosides are presumed to play a role in cell growth and differentiation. Using monoclonal antibodies directed against G.sub.D3, a disialoganglioside expressed predominantly by cells of neuroectodermal origin, we have found that G.sub.D3 is expressed by a subpopulation of cells of the immune system including: a) fetal thymocytes in subcortical regions and near vessels, 2) lymph node lymphocytes in interfollicular areas and near vessels, and 3) a small subset of T cells in the peripheral blood. Mouse monoclonal antibodies (two IgGs, one IgM and F(ab').sub.2 fragments) reacting with G.sub.D3 were found to stimulate proliferation of T cells derived from peripheral blood. Proliferation induced by binding to G.sub.D3 could be augmented by exogenous IL-2, PMA, PHA or Protein A.

    摘要翻译： 细胞表面神经节苷脂被认为在细胞生长和分化中起作用。 使用针对GD3的单克隆抗体，主要由神经外胚层起源的细胞表达的二唾液酸神经节苷脂，我们发现GD3由免疫系统细胞亚群表达，包括：a）皮质下区域和近血管的胎儿胸腺细胞，2）淋巴结 淋巴细胞在滤泡内区域和近血管，以及3）外周血中T细胞的一小部分。 发现与GD3反应的小鼠单克隆抗体（两个IgG，一个IgM和F（ab'）2片段）刺激来自外周血的T细胞的增殖。 通过与GD3结合诱导的增殖可以通过外源IL-2，PMA，PHA或蛋白A增强。